Evidence map›Paper›PMID 25504050›Full record

ArticlePlant cell reports2015

The pollen- and embryo-specific Arabidopsis DLL promoter bears good potential for application in marker-free Cre/loxP self-excision strategy.

Zuzana Polóniová, Martin Jopčík, Ildikó Matušíková, Jana Libantová, Jana Moravčíková

Abstract read
PubMed Publisher
In one paragraph

Article in Plant cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Transgene Bioconfinement: Don't Flow There.Plants (Basel, Switzerland) · 2023
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zuzana PolóniováInstitute of Plant Genetics and Biotechnology, Slovak Academy of Sciences, Akademicka 2, P.O. Box 39A, 95 007, Nitra, Slovak Republic, zuzana.poloniova@savba.sk.
Martin Jopčík
Ildikó Matušíková
Jana Libantová
Jana Moravčíková

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

key messageMarker-free transgenic plants can be generated with high efficiency by using the Cre/ lox P self-excision system controlled by the pollen- and embryo-specific Arabidopsis DLL promoter. In this work, we aimed to study the feasibility of using the pollen- and embryo-specific DLL promoter of the At4g16160 gene from Arabidopsis thaliana in a Cre/loxP self-excision strategy. A Cre/loxP self-excision cassette controlled by the DLL promoter was introduced into the tobacco genome via Agrobacterium-mediated transformation. No evidence for premature activation of the Cre/loxP system was observed in primary transformants. The efficiency of nptII removal during pollen and embryo development was investigated in transgenic T1 progenies derived from eight self- and four cross-pollinated T0 lines, respectively. Segregation and rooting assays were performed to select recombined T1 plants. Molecular analyses of these plants confirmed the excision event in all analysed T0 lines and marker-free transgenic T1 plants were obtained with efficiency of up to 96.2%. The Arabidopsis DLL promoter appears to be a strong candidate to drive Cre-mediated recombination not only in tobacco as a model plant, but also in other plant species.

Indexed as

Plants, Genetically ModifiedAgrobacteriumArabidopsis ProteinsBase SequenceGene Expression Regulation, PlantGenetic MarkersGenetic VectorsIntegrasesIon ChannelsMolecular Sequence DataNicotianaPollenPromoter Regions, GeneticSeedsSodium-Phosphate Cotransporter Proteins, Type IITransformation, BacterialArabidopsis ProteinsCre recombinaseGenetic MarkersIntegrasesIon ChannelsOEP16-L protein, ArabidopsisSodium-Phosphate Cotransporter Proteins, Type II

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.